一种完全可降解的 triboelectric 迷走神经刺激器,用于减轻不同阶段的心脏重塑和心力衰竭
Zhen Guo1,2,3, Sheng-Yu Chao2,4, Chun-Yan Kong1,3
1Department of Cardiology, Renmin Hospital of Wuhan University, Wuhan, P. R. China.
Nature communications
|January 21, 2026
概括
一个新的可生物降解设备提供自动供电的迷走神经刺激来治疗心力衰竭. 这种创新疗法通过调节乙胆释放来预防和逆转心脏重塑,改善心脏功能.
科学领域:
- 生物医学工程 生物医学工程
- 再生医学是一种再生医学.
- 心血管研究研究心血管研究
背景情况:
- 心力衰竭影响全球数以百万计的人,高死亡率需要新的治疗方法.
- 目前用于心力衰竭的迷走神经刺激装置存在一些局限性,包括电池寿命短,不可降解性和适应性差.
研究的目的:
- 开发一种完全可生物降解的 triboelectric 纳米发电机,用于自动供电的迷走神经刺激.
- 在心力衰竭模型中调查该设备在预防和逆转肌肉心脏重塑方面的有效性.
主要方法:
- 开发一种可生物降解的 triboelectric 纳米发电机,能够自动供电的迷走神经刺激.
- 在小鼠心力衰竭模型中进行体内测试,以评估设备性能和治疗效果.
- 评估心脏功能,病理重塑和基因表达变化.
主要成果:
- 该设备产生了显著的开放电路电压 (9.07V) 和短路电流 (4.19μA).
- 在4周内实现了稳定的刺激,随后是超声波触发的快速降解.
- 神经刺激显著改善了心脏功能,减少了病理重塑,并调节了与心力衰竭相关的基因表达.
结论:
- 这种可生物降解,自动供电的设备为心力衰竭提供了一个有前途的新治疗策略.
- 该技术消除了更换电池和移除设备手术的需要.
- 它为个性化,特定阶段的心力衰竭管理建立了一个范例.
相关概念视频
Heart Failure II: Pathophysiology
790
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
790
Pathophysiology of Heart Failure
3.0K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
3.0K
Heart Failure I: Introduction
729
Heart failure refers to a clinical syndrome caused by structural or functional cardiac disorders that prevent the heart from pumping an adequate amount of blood to meet the body's metabolic needs. This condition often arises from myocardial infarction or ischemia, leading to decreased cardiac output, reduced tissue perfusion, impaired gas exchange, fluid volume imbalance, and decreased functional ability.Heart failure can result from disruptions in the mechanisms that regulate cardiac output...
729
Heart Failure VI: Adjunct Therapies
278
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
278
Heart Failure Drugs: Diuretics
825
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
825
Heart Failure V: Medical Management
227
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
227


